JonesTrading analyst Soumit Roy has maintained their neutral stance on ATYR stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Hold rating due to a combination of factors surrounding the recent trial results and the uncertain future of aTyr Pharma’s key drug candidate, efzofitimod. The Phase 3 EFZO-FIT trial did not achieve the expected reduction in oral corticosteroid use among patients with pulmonary sarcoidosis, which was a significant setback. The unexpected outcome, where a higher percentage of patients in the placebo group reduced their steroid use to zero, raised concerns about the trial’s design and the drug’s efficacy.
Additionally, while management pointed out some positive quality of life outcomes with efzofitimod, Roy remains skeptical about the FDA’s approval based on the current data. The uncertainty surrounding the drug’s future, coupled with the company’s financial situation, has led to the removal of efzofitimod’s contribution from the valuation model until further clarity is obtained. As a result, Roy has opted to downgrade the stock to a Hold rating, awaiting more definitive guidance on the drug’s development path.